Guidance, NICE advice and quality standards in development | Guidance

Showing 101 to 110 of 388

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]	Technology appraisal guidance	TBC
Dostarlimab with docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6530]	Technology appraisal guidance	TBC
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]	Highly specialised technology	TBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]	Technology appraisal guidance	TBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]	Technology appraisal guidance	TBC
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]	Technology appraisal guidance	TBC
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]	Technology appraisal guidance	TBC
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]	Technology appraisal guidance	TBC
Ectopic pregnancy and miscarriage	Quality standard	6 May 2026
Ectopic pregnancy and miscarriage: diagnosis and initial management (update)	NICE guideline	17 June 2026